0.9604
price down icon3.14%   -0.0311
after-market アフターアワーズ: .99 0.0296 +3.08%
loading
前日終値:
$0.9915
開ける:
$0.97
24時間の取引高:
20,570
Relative Volume:
0.30
時価総額:
$39.83M
収益:
-
当期純損益:
$-74.56M
株価収益率:
-0.4921
EPS:
-1.9516
ネットキャッシュフロー:
$-60.27M
1週間 パフォーマンス:
-8.53%
1か月 パフォーマンス:
-14.25%
6か月 パフォーマンス:
-45.74%
1年 パフォーマンス:
-51.74%
1日の値動き範囲:
Value
$0.96
$0.99
1週間の範囲:
Value
$0.95
$1.1499
52週間の値動き範囲:
Value
$0.95
$3.46

Rallybio Corp Stock (RLYB) Company Profile

Name
名前
Rallybio Corp
Name
セクター
Healthcare (1205)
Name
電話
203- 859-3820
Name
住所
234 CHURCH STREET, NEW HAVEN
Name
職員
25
Name
Twitter
Name
次回の収益日
Name
最新のSEC提出書
Name
RLYB's Discussions on Twitter

RLYB を他の銘柄と比較する

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
RLYB 0.9604 39.83M 0 -74.56M -60.27M -1.9516
VRTX 467.01 119.87B 10.63B -479.80M -1.35B 13.33
REGN 762.00 83.27B 13.85B 4.65B 3.32B 35.06
ARGX 567.90 33.96B 1.86B -40.29M -1.28B -4.16
ALNY 232.27 30.18B 2.09B -332.26M 16.06M -4.14
BNTX 101.87 24.42B 3.30B -501.07M 1.03B 11.54

Rallybio Corp Stock (RLYB) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2023-04-17 開始されました H.C. Wainwright Buy
2023-04-10 開始されました Wedbush Outperform
2022-12-09 開始されました JP Morgan Overweight
2022-02-22 開始されました JMP Securities Mkt Outperform
2021-08-23 開始されました Cowen Outperform
2021-08-23 開始されました Evercore ISI Outperform
2021-08-23 開始されました Jefferies Buy
すべてを表示

Rallybio Corp (RLYB) 最新ニュース

pulisher
Nov 15, 2024

Rallybio stock hits 52-week low at $0.96 amid market challenges - Investing.com India

Nov 15, 2024
pulisher
Nov 12, 2024

FMR LLC Acquires Shares in Rallybio Corp - GuruFocus.com

Nov 12, 2024
pulisher
Nov 12, 2024

HC Wainwright Issues Pessimistic Forecast for Rallybio (NASDAQ:RLYB) Stock Price - Defense World

Nov 12, 2024
pulisher
Nov 08, 2024

Staff cuts help New Haven-based biotech Rallybio reduce 3Q loss - Hartford Business Journal

Nov 08, 2024
pulisher
Nov 07, 2024

Rallybio Reports Third Quarter 2024 Financial Results and Provides Business Updates - BioSpace

Nov 07, 2024
pulisher
Nov 07, 2024

Rallybio Narrows Losses 37%, Advances RLYB212 Trial with $75M Cash Runway | RLYB Stock News - StockTitan

Nov 07, 2024
pulisher
Nov 05, 2024

Two former Alexion leaders fight through a tough market to maintain a rare disease biotech - PharmaVoice

Nov 05, 2024
pulisher
Oct 30, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges - Investing.com Canada

Oct 30, 2024
pulisher
Oct 30, 2024

Rallybio advances novel FNAIT prevention trial By Investing.com - Investing.com Canada

Oct 30, 2024
pulisher
Oct 29, 2024

Rallybio advances novel FNAIT prevention trial - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio stock plunges to 52-week low at $0.99 amid market challenges By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio’s trial applications of RLYB212 in pregnant women with FNAIT approved - TipRanks

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio to Begin First Clinical Trial for Prevention of Rare Pregnancy Blood Disorder - Femtech Insider

Oct 29, 2024
pulisher
Oct 29, 2024

Rallybio Announces Approval of Clinical Trial Applications for Phase 2 Trial of RLYB212 in Pregnant Women at Higher Risk of Alloimmunization and FNAIT - Business Wire

Oct 29, 2024
pulisher
Oct 23, 2024

Rallybio stock hits 52-week low at $1.08 amid market challenges - Investing.com Australia

Oct 23, 2024
pulisher
Oct 14, 2024

Rallybio stock plunges to 52-week low at $1.08 amid market challenges - Investing.com

Oct 14, 2024
pulisher
Oct 01, 2024

Rallybio shares hold Buy rating on HPP treatment data - Investing.com India

Oct 01, 2024
pulisher
Sep 30, 2024

Rallybio's SWOT analysis: FNAIT treatment stock poised for growth amid challenges - Investing.com

Sep 30, 2024
pulisher
Sep 30, 2024

Data Demonstrating ENPP1 Inhibition as a Therapeutic Approach for Later-onset Hypophosphatasia Presented at the American Society for Bone and Mineral Research 2024 Annual Meeting - StockTitan

Sep 30, 2024
pulisher
Sep 24, 2024

Rallybio reveals higher FNAIT risk across populations By Investing.com - Investing.com Australia

Sep 24, 2024
pulisher
Sep 23, 2024

Rallybio reveals higher FNAIT risk across populations - Investing.com

Sep 23, 2024
pulisher
Sep 23, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the American Society of Human Genetics 2024 Annual Meeting - Business Wire

Sep 23, 2024
pulisher
Sep 19, 2024

Rallybio Co. (NASDAQ:RLYB) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Rallybio announces board member resignation - Investing.com

Sep 18, 2024
pulisher
Sep 17, 2024

Rallybio announces board member resignation By Investing.com - Investing.com UK

Sep 17, 2024
pulisher
Sep 17, 2024

Dr. Kush Parmar Steps Down from Rallybio’s Board and Committee - TipRanks

Sep 17, 2024
pulisher
Sep 17, 2024

Rallybio Corporation Announces Resignation of Kush Parmar as Member of Board and Chair of Nominating and Corporate Governance Committee, Effective October 31, 2024 - Marketscreener.com

Sep 17, 2024
pulisher
Sep 12, 2024

RLYBRallybio Corporation Latest Stock News & Market Updates - StockTitan

Sep 12, 2024
pulisher
Sep 10, 2024

Rallybio to Present Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse Populations at the NORD Breakthrough Summit - Business Wire

Sep 10, 2024
pulisher
Sep 09, 2024

Fierce Names Rallybio to the 2024 Fierce 50 List as an Innovation Honoree - Business Wire

Sep 09, 2024
pulisher
Sep 09, 2024

Rallybio - FiercePharma

Sep 09, 2024
pulisher
Sep 04, 2024

Rallybio stock plunges to 52-week low, hits $1.09 - Investing.com

Sep 04, 2024
pulisher
Sep 04, 2024

Rallybio (NASDAQ:RLYB) Given “Buy” Rating at HC Wainwright - Defense World

Sep 04, 2024
pulisher
Sep 03, 2024

Rallybio reiterated at Buy at H.C. Wainwright on FNAIT drug data - Investing.com

Sep 03, 2024
pulisher
Aug 29, 2024

Rallybio advances RLYB212 to phase 2 for FNAIT prevention - Investing.com India

Aug 29, 2024
pulisher
Aug 29, 2024

Rallybio Announces Publication of RLYB212 Phase 1 Proof-of-Concept Study Results in Thrombosis and Haemostasis - Business Wire

Aug 29, 2024
pulisher
Aug 28, 2024

We Think Rallybio (NASDAQ:RLYB) Needs To Drive Business Growth Carefully - Simply Wall St

Aug 28, 2024
pulisher
Aug 27, 2024

Rallybio to Present at Upcoming Investor Conferences - Elk Valley Times

Aug 27, 2024
pulisher
Aug 21, 2024

Rallybio (RLYB) Upgraded to Buy: What Does It Mean for the Stock? - MSN

Aug 21, 2024
pulisher
Aug 15, 2024

Rallybio stock plunges to 52-week low at $1.09 amid market challenges - Investing.com Australia

Aug 15, 2024
pulisher
Aug 15, 2024

HC Wainwright Comments on Rallybio Co.’s Q3 2024 Earnings (NASDAQ:RLYB) - Defense World

Aug 15, 2024

Rallybio Corp (RLYB) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading
$18.98
price up icon 3.66%
$76.97
price up icon 1.23%
$39.51
price up icon 7.22%
$359.21
price down icon 0.88%
$187.69
price down icon 0.58%
$101.87
price up icon 2.00%
大文字化:     |  ボリューム (24 時間):